The omission might have been done with intent. Think about it. Keep it low profile to keep revlimid patent challengers (which settled for gradual market penetration in 2022) hopeful that they will soon have a market share in myeloma but KOLs will want CC-220 CC-480 for their clients once they are approved.
same strategy being applied with nivolumab subcutaneous updates which might be a new formulation.
At times silence is golden